RecombinantRabMAb

Recombinant Anti-LRRK2 (phospho S1292) antibody [MJFR-19-7-8] - Low endotoxin, Azide free (ab206035)

Submit a review Submit a question
Western blot - Anti-LRRK2 (phospho S1292) antibody [MJFR-19-7-8] - Low endotoxin, Azide free (ab206035)
  • Anti-LRRK2 (phospho S1292) antibody [MJFR-19-7-8] - Low endotoxin, Azide free (ab206035)

Key features and details

  • Produced recombinantly (animal-free) for high batch-to-batch consistency and long term security of supply
  • Rabbit monoclonal [MJFR-19-7-8] to LRRK2 (phospho S1292) - Low endotoxin, Azide free
  • Suitable for: WB
  • Reacts with: Human

Overview

  • Product name

    Anti-LRRK2 (phospho S1292) antibody [MJFR-19-7-8] - Low endotoxin, Azide free
    See all LRRK2 primary antibodies

  • Description

    Rabbit monoclonal [MJFR-19-7-8] to LRRK2 (phospho S1292) - Low endotoxin, Azide free

  • Host species

    Rabbit

  • Tested Applications & Species

    Application Species
    WB
    Human
    See all applications and species data

  • Immunogen

    Synthetic peptide. This information is proprietary to Abcam and/or its suppliers.

  • Positive control

    • GFP-LRRK2 wt transfected HEK293 lysate subjected to immunoprecipitation with GFP trap agarose; GFP-LRRK2 mutant G 2019S transfected HEK293 lysate subjected to immunoprecipitation with GFP trap agarose; LRRK2 wt transfected HEK293 lysate; LRRK2 mutant G2019S transfected HEK293 lysate.

  • General notes

    ab206035 is the Low endotoxin, azide-free version of ab203181 This format is designed for in vitro and in vivo studies, including neutralization, blocking or activation/proliferation.

    Our Low endotoxin, azide-free formats have low endotoxin level (≤ 1 EU/ml, determined by the LAL assay) and are free from azide, to achieve consistent experimental results in functional assays.

    This antibody was developed with support from The Michael J. Fox Foundation.

     

    This product is a recombinant monoclonal antibody, which offers several advantages including:

    • - High batch-to-batch consistency and reproducibility
    • - Improved sensitivity and specificity
    • - Long-term security of supply
    • - Animal-free production
    For more information see here.

    Our RabMAb® technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to RabMAb® patents.

    The Life Science industry has been in the grips of a reproducibility crisis for a number of years. Abcam is leading the way in addressing the problem with our range of recombinant monoclonal antibodies and knockout edited cell lines for gold-standard validation.

    One factor contributing to the crisis is the use of antibodies that are not suitable. This can lead to misleading results and the use of incorrect data informing project assumptions and direction. To help address this challenge, we have introduced an application and species grid on our primary antibody datasheets to make it easy to simplify identification of the right antibody for your needs.

    Learn more here.

Properties

Applications

The Abpromise guarantee

Our Abpromise guarantee covers the use of ab206035 in the following tested applications.

The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.

Guaranteed

Tested applications are guaranteed to work and covered by our Abpromise guarantee.

Predicted

Predicted to work for this combination of applications and species but not guaranteed.

Incompatible

Does not work for this combination of applications and species.

Application Species
WB
Human
Application Abreviews Notes
WB
Use at an assay dependent concentration. Detects a band of approximately 286 kDa (predicted molecular weight: 286 kDa).
Notes
WB
Use at an assay dependent concentration. Detects a band of approximately 286 kDa (predicted molecular weight: 286 kDa).

Target

  • Function

    Positively regulates autophagy through a calcium-dependent activation of the CaMKK/AMPK signaling pathway. The process involves activation of nicotinic acid adenine dinucleotide phosphate (NAADP) receptors, increase in lysosomal pH, and calcium release from lysosomes. Together with RAB29, plays a role in the retrograde trafficking pathway for recycling proteins, such as mannose 6 phosphate receptor (M6PR), between lysosomes and the Golgi apparatus in a retromer-dependent manner. Regulates neuronal process morphology in the intact central nervous system (CNS). Plays a role in synaptic vesicle trafficking. Phosphorylates PRDX3. Has GTPase activity. May play a role in the phosphorylation of proteins central to Parkinson disease.

  • Tissue specificity

    Expressed in the brain. Expressed in pyramidal neurons in all cortical laminae of the visual cortex, in neurons of the substantia nigra pars compacta and caudate putamen (at protein level). Expressed throughout the adult brain, but at a lower level than in heart and liver. Also expressed in placenta, lung, skeletal muscle, kidney and pancreas. In the brain, expressed in the cerebellum, cerebral cortex, medulla, spinal cord occipital pole, frontal lobe, temporal lobe and putamen. Expression is particularly high in brain dopaminoceptive areas.

  • Involvement in disease

    Parkinson disease 8

  • Sequence similarities

    Belongs to the protein kinase superfamily. TKL Ser/Thr protein kinase family.
    Contains 12 LRR (leucine-rich) repeats.
    Contains 1 protein kinase domain.
    Contains 1 Roc domain.
    Contains 7 WD repeats.

  • Domain

    The seven-bladed WD repeat region is critical for synaptic vesicle trafficking and mediates interaction with multiple vesicle-associated presynaptic proteins.
    The Roc domain mediates homodimerization and regulates kinase activity.

  • Post-translational
    modifications

    Autophosphorylated.

  • Cellular localization

    Membrane. Cytoplasm. Perikaryon. Mitochondrion. Golgi apparatus. Cell projection, axon. Cell projection, dendrite. Endoplasmic reticulum. Cytoplasmic vesicle, secretory vesicle, synaptic vesicle membrane. Endosome. Lysosome. Mitochondrion outer membrane. Mitochondrion inner membrane. Mitochondrion matrix. Predominantly associated with intracytoplasmic vesicular and membranous structures (By similarity). Localized in the cytoplasm and associated with cellular membrane structures. Predominantly associated with the mitochondrial outer membrane of the mitochondria. Colocalized with RAB29 along tubular structures emerging from Golgi apparatus. Localizes in intracytoplasmic punctate structures of neuronal perikarya and dendritic and axonal processes.
  • Information by UniProt

  • Database links

    • Alternative names

      • augmented in rheumatoid arthritis 17 antibody
      • AURA17 antibody
      • Dardarin antibody
      • Leucine rich repeat kinase 2 antibody
      • leucine rich repeat serine threonine protein kinase 2 antibody
      • Leucine-rich repeat serine/threonine-protein kinase 2 antibody
      • LRRK 2 antibody
      • LRRK2 antibody
      • LRRK2_HUMAN antibody
      • PARK 8 antibody
      • PARK8 antibody
      • RIPK7 antibody
      • ROCO 2 antibody
      • ROCO2 antibody
      see all

    Images

    • Western blot - Anti-LRRK2 (phospho S1292) antibody [MJFR-19-7-8] - Low endotoxin, Azide free (ab206035)
      Western blot - Anti-LRRK2 (phospho S1292) antibody [MJFR-19-7-8] - Low endotoxin, Azide free (ab206035)
      All lanes : Anti-LRRK2 (phospho S1292) antibody [MJFR-19-7-8] (ab203181) at 1 µg/ml

      Lane 1 : GFP-LRRK2 wt transfected HEK293 lysate subjected to immunoprecipitation with GFP trap agarose
      Lane 2 : GFP-LRRK2 mutant D2017A transfected HEK293 lysate subjected to immunoprecipitation with GFP trap agarose
      Lane 3 : GFP-LRRK2 mutant S1292A/G2019S transfected HEK293 lysate subjected to immunoprecipitation with GFP trap agarose
      Lane 4 : GFP-LRRK2 mutant G2019S transfected HEK293 lysate subjected to immunoprecipitation with GFP trap agarose

      Lysates/proteins at 10 µg per lane.

      Secondary
      All lanes : Goat anti-rabbit (IRDye 800) at 1/10000 dilution

      Predicted band size: 286 kDa



      This WB data was generated using the sam anti-LRRK2 (phospho S1292) antibody clone, MJFR-19-7-8, in a different buffer formulation (cat# ab203181).

      Blocking/Dilution buffer: 5% BSA/TBST.

      The image is provided by Dr. Jeremy Nicols, Parkinson’s Institute, Sunnyvale, CA, USA.

      G2019S mutation results in an increased LRRK2 auto-phosphorylation including S1292 (lane 4).

      Observed band size: 286 + 27 (GFP) = 313 kDa.

    • Anti-LRRK2 (phospho S1292) antibody [MJFR-19-7-8] - Low endotoxin, Azide free (ab206035)
      Anti-LRRK2 (phospho S1292) antibody [MJFR-19-7-8] - Low endotoxin, Azide free (ab206035)

    References (0)

    Publishing research using ab206035? Please let us know so that we can cite the reference in this datasheet.

    ab206035 has not yet been referenced specifically in any publications.

    Customer reviews and Q&As

    Show All Reviews Q&A
    Submit a review Submit a question

    There are currently no Customer reviews or Questions for ab206035.
    Please use the links above to contact us or submit feedback about this product.

    Please note: All products are "FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC PROCEDURES"
    For licensing inquiries, please contact partnerships@abcam.com